Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | ICMT | O60725 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22863382 | 1.00 | ALOX5 (0.33) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL13663949 | 0.96 | ALOX5 (0.35) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL9880201 | 0.93 | ALOX5 (0.38) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL30075067 | 0.90 | ALOX5 (0.37) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29425557 | 0.89 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL22863220 | 0.88 | ALOX5 (0.37) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL31689053 | 0.88 | ALOX5 (0.37) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29584654 | 0.88 | ALOX5 (0.37) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29403709 | 0.88 | ALOX5 (0.37) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL24827775 | 0.87 | ALOX5 (0.38) | ALOX5APPPTPN1NR1H4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322381-A1 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322381-A1 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | PROC, FABP7, TIMP3 | ALOX5 400/4885APP 767/4885PTPN1 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.